Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

AI model turns POCUS images into accurate structural heart evaluations
Researchers see potential for this technology to make cardiac screening much easier for physicians who are not trained cardiologists.
Faster treatments, better outcomes: 5 key takeaways from new stroke guideline
The American Stroke Association's first major update in 7 years highlights the importance of coordinated care and expands patient access to critical treatments. It also includes the first detailed recommendations for treating stroke in pediatric patients.
FAPI PET shows promise to make a big impact in cardiovascular imaging
More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
Abbott executive who led TAVR, Tendyne divisions announces exit
Chris Waddell, a medtech executive focused on various structural heart technologies, is leaving Abbott after several years to "recharge" and pursue a new opportunity.
Heavy cannabis use may not impact heart surgery outcomes
Cannabis use has been linked to multiple cardiovascular risks, but less is known about how it may affect patients who undergo major cardiac surgery.

Abbott secures key approval for new catheter capable of PFA, radiofrequency ablation

The TactiFlex Duo Ablation Catheter, Sensor Enabled was designed to switch from PFA to radiofrequency ablation as needed, providing electrophysiologists with options when treating AFib patients.

Anthony Fletcher, MD, FACC FAHA, FSCAI, president of the Association of Black Cardiologists (ABC), and an interventional cardiologist at CHI St. Vincent Heart Clinic Arkansas, Little Rock, explains the results of a recent ABC survey looking at the level of awareness among providers and communities in cardiology care deserts in the South. He said there was a poor level of understanding about LDL-C management and Lp(a) awareness among both primary care providers and patients in these underserved areas.

New ABC campaign works to improve care in cardiology deserts

Association of Black Cardiologists President Anthony Fletcher, MD, discusses the group's efforts to educate patients in Louisiana, Arkansas, Georgia and Mississippi.

Medical societies, medtech companies and clinicians weigh in as CMS considers sweeping TAVR changes

CMS is considering substantial updates to its TAVR policies, including coverage for asymptomatic patients. Some stakeholders are excited, embracing the possibility of expanded indications and fewer restrictions. Others are concerned that the changes would be too much, too soon.

New-look heart failure treatment shows early promise

Reducing the activity of a specific protein could provide significant relief for many heart failure patients.

Vascular surgeon indicted for murder of ex-wife and her husband

Michael McKee is accused of making the journey from Illinois to Ohio and then shooting the two victims in their home on Dec. 30. He was arrested after surveillance footage showed his car at the scene before and after the murders.

heart data research doctor cardiologist AI

Post-TAVR echocardiography helps predict a patient’s long-term risk of SVD

Postprocedural gradients can tell cardiologists a lot about a patient's long-term risk of structural valve deterioration.

CGuard Prime carotid stent system was cleared by the U.S. Food and Drug Administration (FDA) in June 2025.

Pivotal trial highlights safety, effectiveness of FDA-approved carotid stent

The CGuard Prime carotid stent system from InspireMD was approved by the FDA in 2025. These data confirm the device's ability to reduce a patient's stroke risk during treatment.

FDA announces Class I recall on anesthesia vaporizers due to risk of chemical exposure

Vapor 2000 and Vapor 3000 devices manufactured by Draegar were improperly cleaned after parts were soldered on, meaning toxic metals could mix with medical gases. Due to the high risk posed to patient health, this recall has earned the FDA’s most serious designation.

Clinical

AI model turns POCUS images into accurate structural heart evaluations

Faster treatments, better outcomes: 5 key takeaways from new stroke guideline

FAPI PET shows promise to make a big impact in cardiovascular imaging

Abbott executive who led TAVR, Tendyne divisions announces exit

Heavy cannabis use may not impact heart surgery outcomes